TABLE 1.

The combinatorial complexity of domain architecture in fusion-driven sarcoma.

DNA-binding domain	Fusion partner	Malignancy
$\text{TFE3}$	$\text{ASPL}$	Alveolar Soft Part Sarcoma
$\text{TFE3}$	ASPSCR1	Alveolar Soft Part Sarcoma
$\text{ATF1}$	EWSR1	Clear cell sarcoma
$\text{CREB1}$	EWSR1	Clear cell sarcoma
WT1	EWSR1	Desmoplastic round cell tumor
$\text{CAMTA1}$	WWTR1	Epithelioid hemangioendothelioma
$\text{YAP1}$	$\text{TFE3*}$	Epithelioid hemangioendothelioma
$\text{FLI}$	EWSR1	Ewing Sarcoma
$\text{DDIT3}$	FUS	Myxoid/round liposarcoma
$\text{NCOA2}$	VGLL2	Rhabdomyosarcoma
$\text{PAX3}$	FOXO1	Rhabdomyosarcoma
$\text{PAX7}$	FOXO1	Rhabdomyosarcoma
$\text{PAX3}$	$\text{NCOA1**}$	Rhabdomyosarcoma
$\text{PAX3}$	$\text{NCOA2**}$	Rhabdomyosarcoma
$\text{SS18}$	$\text{SSX1, SSX2, SSX4}$	Synovial Sarcoma
$\text{DUX4}$	$\text{CIC**}$	Undifferentiated round cell sarcoma

Domains and classes are defined through color coding (columns 1, 2) with driver function in malignancies (column 3). The (**) denotes fusion partner is also DBD. In the DNA-binding domain (DBD) column, $\text{bHLH}$ , $\text{PD}$ , $\text{HD}$ , $\text{bZIP/leucine zipper}$ , zinc finger, $\text{TEAD domain}$ , $\text{ETS family}$ , and $\text{SWI/SNF}$ are color coded in the text. In the Fusion partner column, $\text{Enzyme}$ , $\text{Reader/structural domain}$ , $\text{Activator domain}$ , and $\text{HMG}$ are color coded in the text.